The duration of the study for an individual patient will include:
* The screening period = up to 4 weeks prior to the first administration of SAR3419.
* The treatment period:
* Induction period = 4 to 8 weeks
* Maintenance = up to a total maintenance treatment of 6 months
* A safety follow-up period of 42 days after the last dose.
* Any patient who discontinues the study treatment without disease progression will be followed every 2 months until disease progression, initiation of a new anti-cancer therapy, death or end-of-study date, whatever comes first.
